

CLAIMS

1. Association of a bacterial strain of the species *Faecalibacterium prausnitzii* deposited with the CNCM under accession number CNCM I-4573 with mesalamine or a derivative thereof.
2. Association according to claim 1, wherein the mesalamine derivative is selected from the group consisting of Mesalazine, Olsalazine, 4-ASA (4-Aminosalicylic acid) and Sulfasalazine.
3. Pharmaceutical composition comprising, in a pharmaceutically acceptable medium, an association as defined in claim 1 or 2.
4. Association as defined in claim 1 or 2, for use in the treatment and/or prevention of an inflammatory gastrointestinal disease in an individual.
5. The association for use according to claim 4, wherein the individual is a mammal.
6. The association for use according to claim 4 or 5, wherein the individual is a human being.
7. The association for use according to any one of claims 4 to 6, wherein the inflammatory gastrointestinal disease is an inflammatory bowel disease.
8. The association use according to any one of claims 4 to 7, wherein the inflammatory gastrointestinal disease is a colonic inflammatory bowel disease.
9. The association for use according to claim 8, wherein the colonic inflammatory bowel disease is chosen from the group consisting of Crohn's disease, ulcerative colitis and pouchitis.
10. The association for use according to claim 8 or 9, wherein the colonic inflammatory bowel disease is chosen from the group consisting of Crohn's disease and ulcerative colitis.

11. The association for use according to any one of claims 4 to 10, wherein the association is in a pharmaceutically acceptable medium of a pharmaceutical composition.

12. The association for use according to claim 11, wherein the composition is suitable for the administration of a daily dose of the bacterial strain of the species
5 *Faecalibacterium prausnitzii* deposited with the CNCM under accession number CNCM I-4573 representing from 10^3 bacteria to 10^{12} bacteria, in particular a daily dose representing from 10^4 bacteria to 10^{12} bacteria, more particularly a daily dose representing from 10^6 to 10^{12} bacteria, preferably in the form of a daily dose equivalent to 10^{10} bacteria.

13. The association for use according to claim 11 or 12, wherein the composition
10 is for oral administration, and is in particular chosen from the group consisting of a food product, a beverage, a pharmaceutical product, a nutraceutical, a food additive, a food supplement and a milk product.

14. The association for use according to claim 13, characterized in that the composition is a pharmaceutical product.